View Financial HealthCOFCO Biotechnology 配当と自社株買い配当金 基準チェック /26COFCO Biotechnology配当を支払う会社であり、現在の利回りは0.61%です。主要情報0.6%配当利回り0%バイバック利回り総株主利回り0.6%将来の配当利回りn/a配当成長23.4%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向-45%最近の配当と自社株買いの更新お知らせ • May 30COFCO Biotechnology Co., Ltd. Approves Cash Dividend for the Year 2025COFCO Biotechnology Co., Ltd. held its Annual General Meeting of 2025 on 27 May 2026, during which the following proposal(s) was/were approved: Cash dividend/10 shares (tax included) of CNY 0.30000000 for the year 2025.お知らせ • Jun 28COFCO Biotechnology Co., Ltd. Implements Cash Dividend (A shares) for 2022, Payable on July 03, 2023COFCO Biotechnology Co., Ltd. announced implementation of cash dividend (tax included) (A shares) of CNY 5.70000000 per 10 shares. Record date: 30 June 2023. Ex-date: 03 July 2023. Payment date: 03 July 2023.すべての更新を表示Recent updatesお知らせ • May 30COFCO Biotechnology Co., Ltd. Approves Cash Dividend for the Year 2025COFCO Biotechnology Co., Ltd. held its Annual General Meeting of 2025 on 27 May 2026, during which the following proposal(s) was/were approved: Cash dividend/10 shares (tax included) of CNY 0.30000000 for the year 2025.Board Change • May 20High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 3 experienced directors. No highly experienced directors. Employee Supervisor Zhi Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 24COFCO Biotechnology Co., Ltd., Annual General Meeting, May 27, 2026COFCO Biotechnology Co., Ltd., Annual General Meeting, May 27, 2026, at 14:00 China Standard Time. Location: 22F, Tower A, Zhaotai International Center, Chaoyangmen South Avenue, Chaoyang District, Beijing Chinaお知らせ • Mar 31COFCO Biotechnology Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026お知らせ • Dec 31COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026お知らせ • Sep 30COFCO Biotechnology Co., Ltd. to Report Q3, 2025 Results on Oct 24, 2025COFCO Biotechnology Co., Ltd. announced that they will report Q3, 2025 results on Oct 24, 2025お知らせ • Jul 02COFCO Biotechnology Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025COFCO Biotechnology Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025お知らせ • Apr 26COFCO Biotechnology Co., Ltd., Annual General Meeting, May 20, 2025COFCO Biotechnology Co., Ltd., Annual General Meeting, May 20, 2025, at 14:30 China Standard Time. Location: 22F, Tower A, Zhaotai International Center, Chaoyangmen South Avenue, Chaoyang District, Beijing Chinaお知らせ • Apr 02COFCO Biotechnology Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025お知らせ • Dec 31COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025Reported Earnings • Oct 26Third quarter 2024 earnings released: CN¥0.028 loss per share (vs CN¥0.001 profit in 3Q 2023)Third quarter 2024 results: CN¥0.028 loss per share (down from CN¥0.001 profit in 3Q 2023). Revenue: CN¥5.21b (down 3.7% from 3Q 2023). Net loss: CN¥51.9m (down CN¥54.3m from profit in 3Q 2023). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance.お知らせ • Sep 30COFCO Biotechnology Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024COFCO Biotechnology Co., Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024お知らせ • Sep 21COFCO Biotechnology Co., Ltd. Announces Board ChangesCOFCO Biotechnology Co., Ltd. at its EGM held on 19 September 2024 appointed Zhang Deguo, Zheng Heshan as non-independent director; appointed Zhang Nianchun and Wang Ping as independent director.Reported Earnings • Aug 24Second quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.18 loss in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.02 (up from CN¥0.18 loss in 2Q 2023). Revenue: CN¥5.18b (up 8.2% from 2Q 2023). Net income: CN¥36.6m (up CN¥373.3m from 2Q 2023). Profit margin: 0.7% (up from net loss in 2Q 2023). Revenue is forecast to grow 1.3% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance.お知らせ • Jun 29COFCO Biotechnology Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024COFCO Biotechnology Co., Ltd. announced that they will report first half, 2024 results on Aug 24, 2024Board Change • Jun 12High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 3 experienced directors. 1 highly experienced director. GM & Non-Independent Director De Guo Zhang is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.001 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.013 (up from CN¥0.001 in 1Q 2023). Revenue: CN¥4.73b (up 4.6% from 1Q 2023). Net income: CN¥24.8m (up CN¥23.4m from 1Q 2023). Profit margin: 0.5% (up from 0% in 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance.お知らせ • Apr 26COFCO Biotechnology Co., Ltd., Annual General Meeting, May 16, 2024COFCO Biotechnology Co., Ltd., Annual General Meeting, May 16, 2024, at 14:30 China Standard Time. Location: 22F, Tower A, Zhaitai Int'l Center, Chaoyangmen South Avenue, Chaoyang District, Beijing Chinaお知らせ • Mar 30COFCO Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024お知らせ • Dec 29COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2023 results on Apr 25, 2024New Risk • Nov 23New major risk - Revenue and earnings growthEarnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 0.2% per year over the past 5 years.Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.097 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.001 (down from CN¥0.097 in 3Q 2022). Revenue: CN¥5.41b (up 26% from 3Q 2022). Net income: CN¥2.38m (down 99% from 3Q 2022). Profit margin: 0% (down from 4.2% in 3Q 2022). Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.お知らせ • Sep 30COFCO Biotechnology Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023COFCO Biotechnology Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023Buying Opportunity • Sep 26Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be CN¥8.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making.Buying Opportunity • Aug 31Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 13%. The fair value is estimated to be CN¥8.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Aug 26Second quarter 2023 earnings released: CN¥0.18 loss per share (vs CN¥0.23 profit in 2Q 2022)Second quarter 2023 results: CN¥0.18 loss per share (down from CN¥0.23 profit in 2Q 2022). Revenue: CN¥4.79b (down 8.4% from 2Q 2022). Net loss: CN¥336.7m (down 177% from profit in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 10% per year, which means it is performing significantly worse than earnings.お知らせ • Jun 28COFCO Biotechnology Co., Ltd. Implements Cash Dividend (A shares) for 2022, Payable on July 03, 2023COFCO Biotechnology Co., Ltd. announced implementation of cash dividend (tax included) (A shares) of CNY 5.70000000 per 10 shares. Record date: 30 June 2023. Ex-date: 03 July 2023. Payment date: 03 July 2023.お知らせ • May 20+ 1 more updateCOFCO Biotechnology Co., Ltd. Approves the Election of Wang Laichun as a Non-Employee SupervisorCOFCO Biotechnology Co., Ltd. at its Annual General Meeting of 2022 held on 18 May 2023, approved the election of Wang Laichun as a Non-Employee Supervisor.Reported Earnings • Apr 16Full year 2022 earnings released: EPS: CN¥0.57 (vs CN¥0.61 in FY 2021)Full year 2022 results: EPS: CN¥0.57 (down from CN¥0.61 in FY 2021). Revenue: CN¥19.9b (down 15% from FY 2021). Net income: CN¥1.06b (down 6.6% from FY 2021). Profit margin: 5.3% (up from 4.8% in FY 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: CN¥0.097 (vs CN¥0.13 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.097 (down from CN¥0.13 in 3Q 2021). Revenue: CN¥4.29b (down 29% from 3Q 2021). Net income: CN¥179.7m (down 24% from 3Q 2021). Profit margin: 4.2% (up from 3.9% in 3Q 2021). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 25Second quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.19 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.23 (up from CN¥0.19 in 2Q 2021). Revenue: CN¥5.23b (down 18% from 2Q 2021). Net income: CN¥436.7m (up 25% from 2Q 2021). Profit margin: 8.4% (up from 5.5% in 2Q 2021). The increase in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 8.2%, compared to a 42% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 30First quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.19 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.19 (down from CN¥0.19 in 1Q 2021). Revenue: CN¥5.38b (down 4.3% from 1Q 2021). Net income: CN¥349.0m (down 1.9% from 1Q 2021). Profit margin: 6.5% (up from 6.3% in 1Q 2021). Over the next year, revenue is forecast to grow 19%, compared to a 43% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Board Change • Apr 27High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Oct 31Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.091 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥6.06b (up 30% from 3Q 2020). Net income: CN¥234.9m (up 40% from 3Q 2020). Profit margin: 3.9% (up from 3.6% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Board Change • Sep 12High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Sep 09High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Aug 28Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.14 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥6.38b (up 22% from 2Q 2020). Net income: CN¥350.2m (up 32% from 2Q 2020). Profit margin: 5.5% (up from 5.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 15Full year 2020 earnings released: EPS CN¥0.32 (vs CN¥0.32 in FY 2019)The company reported a solid full year result with improved revenues, although earnings and profit margins were flat. Full year 2020 results: Revenue: CN¥19.9b (up 2.2% from FY 2019). Net income: CN¥593.1m (flat on FY 2019). Profit margin: 3.0% (in line with FY 2019).Valuation Update With 7 Day Price Move • Feb 06Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥9.07, the stock is trading at a trailing P/E ratio of 22.7x, down from the previous P/E ratio of 27.3x. This compares to an average P/E of 34x in the Chemicals industry in China. Total returns to shareholders over the past year are 11%.Is New 90 Day High Low • Jan 25New 90-day high: CN¥10.11The company is up 19% from its price of CN¥8.47 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 25% over the same period.Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥9.64, the stock is trading at a trailing P/E ratio of 24.2x, up from the previous P/E ratio of 20.8x. This compares to an average P/E of 36x in the Chemicals industry in China. Total returns to shareholders over the past year are 43%.Is New 90 Day High Low • Jan 05New 90-day high: CN¥9.64The company is up 15% from its price of CN¥8.39 on 30 September 2020. The Chinese market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 16% over the same period.Reported Earnings • Oct 26Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥737.4m, up 120% from the prior year. Total revenue was CN¥19.6b over the last 12 months, up 6.2% from the prior year.決済の安定と成長配当データの取得安定した配当: 000930は 10 年未満配当金を支払っており、この間、支払額は 変動性 が高かった。増加する配当: 000930の配当金は増加していますが、同社は7年間しか配当金を支払っていません。配当利回り対市場COFCO Biotechnology 配当利回り対市場000930 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (000930)0.6%市場下位25% (CN)0.4%市場トップ25% (CN)2.1%業界平均 (Chemicals)1.2%アナリスト予想 (000930) (最長3年)n/a注目すべき配当: 000930の配当金 ( 0.61% ) はCN市場の配当金支払者の下位 25% ( 0.38% ) よりも高くなっています。高配当: 000930の配当金 ( 0.61% ) はCN市場の配当金支払者の上位 25% ( 2.13% ) と比較すると低いです。株主への利益配当収益カバレッジ: 000930は配当金を支払っていますが、会社は利益を上げていません。株主配当金キャッシュフローカバレッジ: 000930は 現金配当性向 ( 12.8% ) が低いため、配当金の支払いはキャッシュフローによって完全にカバーされています。高配当企業の発掘7D1Y7D1Y7D1YCN 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/14 07:09終値2026/06/12 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋COFCO Biotechnology Co., Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Xia ShengCitic Securities Co., Ltd.Wei LiuHaitong International Research LimitedJiao ChenIndustrial Securities Co. Ltd.1 その他のアナリストを表示
お知らせ • May 30COFCO Biotechnology Co., Ltd. Approves Cash Dividend for the Year 2025COFCO Biotechnology Co., Ltd. held its Annual General Meeting of 2025 on 27 May 2026, during which the following proposal(s) was/were approved: Cash dividend/10 shares (tax included) of CNY 0.30000000 for the year 2025.
お知らせ • Jun 28COFCO Biotechnology Co., Ltd. Implements Cash Dividend (A shares) for 2022, Payable on July 03, 2023COFCO Biotechnology Co., Ltd. announced implementation of cash dividend (tax included) (A shares) of CNY 5.70000000 per 10 shares. Record date: 30 June 2023. Ex-date: 03 July 2023. Payment date: 03 July 2023.
お知らせ • May 30COFCO Biotechnology Co., Ltd. Approves Cash Dividend for the Year 2025COFCO Biotechnology Co., Ltd. held its Annual General Meeting of 2025 on 27 May 2026, during which the following proposal(s) was/were approved: Cash dividend/10 shares (tax included) of CNY 0.30000000 for the year 2025.
Board Change • May 20High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 3 experienced directors. No highly experienced directors. Employee Supervisor Zhi Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 24COFCO Biotechnology Co., Ltd., Annual General Meeting, May 27, 2026COFCO Biotechnology Co., Ltd., Annual General Meeting, May 27, 2026, at 14:00 China Standard Time. Location: 22F, Tower A, Zhaotai International Center, Chaoyangmen South Avenue, Chaoyang District, Beijing China
お知らせ • Mar 31COFCO Biotechnology Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026
お知らせ • Dec 31COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026
お知らせ • Sep 30COFCO Biotechnology Co., Ltd. to Report Q3, 2025 Results on Oct 24, 2025COFCO Biotechnology Co., Ltd. announced that they will report Q3, 2025 results on Oct 24, 2025
お知らせ • Jul 02COFCO Biotechnology Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025COFCO Biotechnology Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025
お知らせ • Apr 26COFCO Biotechnology Co., Ltd., Annual General Meeting, May 20, 2025COFCO Biotechnology Co., Ltd., Annual General Meeting, May 20, 2025, at 14:30 China Standard Time. Location: 22F, Tower A, Zhaotai International Center, Chaoyangmen South Avenue, Chaoyang District, Beijing China
お知らせ • Apr 02COFCO Biotechnology Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025
お知らせ • Dec 31COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025
Reported Earnings • Oct 26Third quarter 2024 earnings released: CN¥0.028 loss per share (vs CN¥0.001 profit in 3Q 2023)Third quarter 2024 results: CN¥0.028 loss per share (down from CN¥0.001 profit in 3Q 2023). Revenue: CN¥5.21b (down 3.7% from 3Q 2023). Net loss: CN¥51.9m (down CN¥54.3m from profit in 3Q 2023). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance.
お知らせ • Sep 30COFCO Biotechnology Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024COFCO Biotechnology Co., Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024
お知らせ • Sep 21COFCO Biotechnology Co., Ltd. Announces Board ChangesCOFCO Biotechnology Co., Ltd. at its EGM held on 19 September 2024 appointed Zhang Deguo, Zheng Heshan as non-independent director; appointed Zhang Nianchun and Wang Ping as independent director.
Reported Earnings • Aug 24Second quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.18 loss in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.02 (up from CN¥0.18 loss in 2Q 2023). Revenue: CN¥5.18b (up 8.2% from 2Q 2023). Net income: CN¥36.6m (up CN¥373.3m from 2Q 2023). Profit margin: 0.7% (up from net loss in 2Q 2023). Revenue is forecast to grow 1.3% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance.
お知らせ • Jun 29COFCO Biotechnology Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024COFCO Biotechnology Co., Ltd. announced that they will report first half, 2024 results on Aug 24, 2024
Board Change • Jun 12High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 3 experienced directors. 1 highly experienced director. GM & Non-Independent Director De Guo Zhang is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.001 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.013 (up from CN¥0.001 in 1Q 2023). Revenue: CN¥4.73b (up 4.6% from 1Q 2023). Net income: CN¥24.8m (up CN¥23.4m from 1Q 2023). Profit margin: 0.5% (up from 0% in 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 26COFCO Biotechnology Co., Ltd., Annual General Meeting, May 16, 2024COFCO Biotechnology Co., Ltd., Annual General Meeting, May 16, 2024, at 14:30 China Standard Time. Location: 22F, Tower A, Zhaitai Int'l Center, Chaoyangmen South Avenue, Chaoyang District, Beijing China
お知らせ • Mar 30COFCO Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024
お知らせ • Dec 29COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2023 results on Apr 25, 2024
New Risk • Nov 23New major risk - Revenue and earnings growthEarnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 0.2% per year over the past 5 years.
Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.097 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.001 (down from CN¥0.097 in 3Q 2022). Revenue: CN¥5.41b (up 26% from 3Q 2022). Net income: CN¥2.38m (down 99% from 3Q 2022). Profit margin: 0% (down from 4.2% in 3Q 2022). Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
お知らせ • Sep 30COFCO Biotechnology Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023COFCO Biotechnology Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023
Buying Opportunity • Sep 26Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be CN¥8.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making.
Buying Opportunity • Aug 31Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 13%. The fair value is estimated to be CN¥8.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Aug 26Second quarter 2023 earnings released: CN¥0.18 loss per share (vs CN¥0.23 profit in 2Q 2022)Second quarter 2023 results: CN¥0.18 loss per share (down from CN¥0.23 profit in 2Q 2022). Revenue: CN¥4.79b (down 8.4% from 2Q 2022). Net loss: CN¥336.7m (down 177% from profit in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 10% per year, which means it is performing significantly worse than earnings.
お知らせ • Jun 28COFCO Biotechnology Co., Ltd. Implements Cash Dividend (A shares) for 2022, Payable on July 03, 2023COFCO Biotechnology Co., Ltd. announced implementation of cash dividend (tax included) (A shares) of CNY 5.70000000 per 10 shares. Record date: 30 June 2023. Ex-date: 03 July 2023. Payment date: 03 July 2023.
お知らせ • May 20+ 1 more updateCOFCO Biotechnology Co., Ltd. Approves the Election of Wang Laichun as a Non-Employee SupervisorCOFCO Biotechnology Co., Ltd. at its Annual General Meeting of 2022 held on 18 May 2023, approved the election of Wang Laichun as a Non-Employee Supervisor.
Reported Earnings • Apr 16Full year 2022 earnings released: EPS: CN¥0.57 (vs CN¥0.61 in FY 2021)Full year 2022 results: EPS: CN¥0.57 (down from CN¥0.61 in FY 2021). Revenue: CN¥19.9b (down 15% from FY 2021). Net income: CN¥1.06b (down 6.6% from FY 2021). Profit margin: 5.3% (up from 4.8% in FY 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: CN¥0.097 (vs CN¥0.13 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.097 (down from CN¥0.13 in 3Q 2021). Revenue: CN¥4.29b (down 29% from 3Q 2021). Net income: CN¥179.7m (down 24% from 3Q 2021). Profit margin: 4.2% (up from 3.9% in 3Q 2021). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 25Second quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.19 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.23 (up from CN¥0.19 in 2Q 2021). Revenue: CN¥5.23b (down 18% from 2Q 2021). Net income: CN¥436.7m (up 25% from 2Q 2021). Profit margin: 8.4% (up from 5.5% in 2Q 2021). The increase in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 8.2%, compared to a 42% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 30First quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.19 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.19 (down from CN¥0.19 in 1Q 2021). Revenue: CN¥5.38b (down 4.3% from 1Q 2021). Net income: CN¥349.0m (down 1.9% from 1Q 2021). Profit margin: 6.5% (up from 6.3% in 1Q 2021). Over the next year, revenue is forecast to grow 19%, compared to a 43% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Board Change • Apr 27High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Oct 31Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.091 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥6.06b (up 30% from 3Q 2020). Net income: CN¥234.9m (up 40% from 3Q 2020). Profit margin: 3.9% (up from 3.6% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Board Change • Sep 12High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Sep 09High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Aug 28Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.14 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥6.38b (up 22% from 2Q 2020). Net income: CN¥350.2m (up 32% from 2Q 2020). Profit margin: 5.5% (up from 5.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 15Full year 2020 earnings released: EPS CN¥0.32 (vs CN¥0.32 in FY 2019)The company reported a solid full year result with improved revenues, although earnings and profit margins were flat. Full year 2020 results: Revenue: CN¥19.9b (up 2.2% from FY 2019). Net income: CN¥593.1m (flat on FY 2019). Profit margin: 3.0% (in line with FY 2019).
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥9.07, the stock is trading at a trailing P/E ratio of 22.7x, down from the previous P/E ratio of 27.3x. This compares to an average P/E of 34x in the Chemicals industry in China. Total returns to shareholders over the past year are 11%.
Is New 90 Day High Low • Jan 25New 90-day high: CN¥10.11The company is up 19% from its price of CN¥8.47 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 25% over the same period.
Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥9.64, the stock is trading at a trailing P/E ratio of 24.2x, up from the previous P/E ratio of 20.8x. This compares to an average P/E of 36x in the Chemicals industry in China. Total returns to shareholders over the past year are 43%.
Is New 90 Day High Low • Jan 05New 90-day high: CN¥9.64The company is up 15% from its price of CN¥8.39 on 30 September 2020. The Chinese market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 16% over the same period.
Reported Earnings • Oct 26Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥737.4m, up 120% from the prior year. Total revenue was CN¥19.6b over the last 12 months, up 6.2% from the prior year.